![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Mahidol University |
---|---|
Information provided by: | Mahidol University |
ClinicalTrials.gov Identifier: | NCT00705510 |
To evaluate the efficacy of 0.05% cyclosporine ophthalmic emulsion (Restasis® , Allergan) versus an artificial tears alone in patients with meibomian gland dysfunction that have abnormal tear quality and quantity by subjective symptoms and signs including tear breakup time
Condition | Intervention | Phase |
---|---|---|
Meibomian Gland Dysfunction |
Drug: 0.05% cyclosporin eye drop |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomain Gland Dysfunction |
Estimated Enrollment: | 74 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator |
Drug: 0.05% cyclosporin eye drop
use the medication twice daily for 3 months
|
B: Placebo Comparator |
Drug: 0.05% cyclosporin eye drop
use the medication twice daily for 3 months
|
Meibomian gland dysfunction patients will divide into 2 groups. One group will have 0.05% cyclosporine opthalmic emulsion and the other will have placebo eye drop twice daily, compare the result in 3 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Had a slit-lamp diagnosis of meibomian gland dysfunction based on the presence of one of the following
Exclusion Criteria:
Contact: Pinnita Prabhasawat, MD | 662-419-7000 ext 8033 | sippb@mahidol.ac.th |
Contact: Wannaree Mahawong, MD | 662-419-7000 ext 8033 | pooh_pu@hotmail.com |
Thailand | |
Department of Ophthalmology; Siriraj Hospital | Recruiting |
Bangkok, Thailand, 10700 | |
Contact: Pinnita Prabhasawat, MD 662-419-7000 ext 8033 sippb@mahidol.ac.th | |
Contact: Wannaree Mahawong, MD 662-419-7000 ext 8033 pooh_pu@hotmail.com |
Principal Investigator: | Pinnita Prabhasawat, MD | Department of Ophthalmology, Siriraj H, Mahidol U |
Responsible Party: | Department of Ophthalmology; Siriraj Hospital ( Pinnita Prabhasawat ) |
Study ID Numbers: | 154/2551(EC1) |
Study First Received: | June 24, 2008 |
Last Updated: | June 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00705510 |
Health Authority: | Thailand: Ethical Committee |
Cyclosporine Unstable tear film Meibomain gland Meibomian gland dysfunction |
Lacerations Pseudoephedrine Cyclosporine Clotrimazole Miconazole Tioconazole Tetrahydrozoline |
Cyclosporins Naphazoline Oxymetazoline Phenylephrine Guaifenesin Ephedrine Phenylpropanolamine |
Respiratory System Agents Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Immunologic Factors Sympathomimetics Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Immunosuppressive Agents |
Pharmacologic Actions Nasal Decongestants Autonomic Agents Antifungal Agents Therapeutic Uses Vasoconstrictor Agents Peripheral Nervous System Agents Antirheumatic Agents Dermatologic Agents |